Clinical Practice

Use the tool below to view all available Prova Series

Mechanism-Driven gMG Therapy: FcRn Antagonists and the Rise of Precision Neurology
Mechanism-Driven gMG Therapy: FcRn Antagonists and the Rise of Precision Neurology
CME/CE
Mechanism-Driven gMG Therapy: FcRn Antagonists and the Rise of Precision Neurology
0.50 credits
- Neelam Goyal, MD
- Christyn Edmundson, MD
0.50 credits
Pruritus In PN and AD: Challenge How You Manage Itch
Pruritus In PN and AD: Challenge How You Manage Itch
CME/CE
Pruritus In PN and AD: Challenge How You Manage Itch
1.00 credit
- Peter A. Lio, MD
1.00 credit
Adjuvant Pembrolizumab Plus Cisplatin-Based Chemoradiation in Locally Advanced HNSCC: First Results From the Randomized Phase 2b ADRISK Trial
Adjuvant Pembrolizumab Plus Cisplatin-Based Chemoradiation in Locally Advanced HNSCC: First Results From the Randomized Phase 2b ADRISK Trial
Oncology and Hematology
Adjuvant Pembrolizumab Plus Cisplatin-Based Chemoradiation in Locally Advanced HNSCC: First Results From the Randomized Phase 2b ADRISK Trial
- Yungan Tao
Patient-Reported Outcomes From the Phase 3 KEYNOTE-689 Trial of Adding Perioperative Pembrolizumab to Standard of Care in Resectable Locally Advanced HNSCC
Patient-Reported Outcomes From the Phase 3 KEYNOTE-689 Trial of Adding Perioperative Pembrolizumab to Standard of Care in Resectable Locally Advanced HNSCC
Oncology and Hematology
Patient-Reported Outcomes From the Phase 3 KEYNOTE-689 Trial of Adding Perioperative Pembrolizumab to Standard of Care in Resectable Locally Advanced HNSCC
- Yungan Tao
Emerging Clinical Evidence for B7-H3–Directed ADCs in ES-SCLC From WCLC 2025
Emerging Clinical Evidence for B7-H3–Directed ADCs in ES-SCLC From WCLC 2025
MinuteCE®
Emerging Clinical Evidence for B7-H3–Directed ADCs in ES-SCLC From WCLC 2025
0.50 program credits
- Luis Paz-Ares, MD, PhD
- Lauren A. Byers, MD
0.50 program credits
MinuteCE®
Transformative Insights: Latest Evidence for B7-H3 ADCs From WCLC and ESMO 2025  
0.50 credits 6 episodes
- Luis Paz-Ares, MD, PhD
- Lauren A. Byers, MD
0.50 credits 6 episodes
Case Application: Frontline Insights—Tackling Newly Diagnosed Myeloma
Case Application: Frontline Insights—Tackling Newly Diagnosed Myeloma
MinuteCE®
Case Application: Frontline Insights—Tackling Newly Diagnosed Myeloma
1.00 program credit
- Joshua Richter, MD
- Noopur Raje, MD
1.00 program credit
Why CELMoDs Matter in Myeloma
Why CELMoDs Matter in Myeloma
MinuteCE®
Why CELMoDs Matter in Myeloma
1.00 program credit
- Sagar Lonial, MD, FACP
1.00 program credit
Data Dive: Clinical Evidence Behind CELMoDs
Data Dive: Clinical Evidence Behind CELMoDs
MinuteCE®
Data Dive: Clinical Evidence Behind CELMoDs
1.00 program credit
- Sagar Lonial, MD, FACP
1.00 program credit
Mastering the Sequence: CELMoDs Across Treatment Lines
Mastering the Sequence: CELMoDs Across Treatment Lines
MinuteCE®
Mastering the Sequence: CELMoDs Across Treatment Lines
1.00 program credit
- Sagar Lonial, MD, FACP
- Noopur Raje, MD
1.00 program credit
 Real-World Ready: Practical Tips for Community Oncologists
 Real-World Ready: Practical Tips for Community Oncologists
MinuteCE®
 Real-World Ready: Practical Tips for Community Oncologists
1.00 program credit
- Joshua Richter, MD
- Sagar Lonial, MD, FACP
1.00 program credit
Chairperson Perspective: Acromegaly Care: Individualized Diagnosis and Management Strategies
Chairperson Perspective: Acromegaly Care: Individualized Diagnosis and Management Strategies
CME/CE
Chairperson Perspective: Acromegaly Care: Individualized Diagnosis and Management Strategies
0.25 credits
- Maria Fleseriu, MD, FACE
0.25 credits
Data Driving Recent Guideline Updates in Neoadjuvant Therapy for Resectable Melanoma
Data Driving Recent Guideline Updates in Neoadjuvant Therapy for Resectable Melanoma
MinuteCE®
Data Driving Recent Guideline Updates in Neoadjuvant Therapy for Resectable Melanoma
1.00 program credit
- John M. Kirkwood, MD
- Sapna Patel, MD
1.00 program credit
Insights From Global Key Opinion Leaders on Regional Regulatory and Guideline Nuances to Optimize Melanoma Management
Insights From Global Key Opinion Leaders on Regional Regulatory and Guideline Nuances to Optimize Melanoma Management
MinuteCE®
Insights From Global Key Opinion Leaders on Regional Regulatory and Guideline Nuances to Optimize Melanoma Management
1.00 program credit
- Hussein Tawbi, MD, PhD
- Paolo A. Ascierto, MD
1.00 program credit
Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma
Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma
MinuteCE®
Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma
1.00 program credit
- Paolo A. Ascierto, MD
- Hussein Tawbi, MD, PhD
1.00 program credit
Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed Stage III Melanoma
Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed Stage III Melanoma
MinuteCE®
Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed Stage III Melanoma
1.00 program credit
- Paolo A. Ascierto, MD
- Hussein Tawbi, MD, PhD
1.00 program credit

Clinical Practice

Popular

Title

Share on ReachMD